Although traditional biomarkers like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) have guided clinical decisions (Figure 5), recent advancements in molecular profiling have brought to light promising novel biomarkers for breast cancer diagnoses, prognoses, and treatment response predictions. This evidence concerns the gene PGR and breast carcinoma.